California State Teachers Retirement System Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

California State Teachers Retirement System trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,255 shares of the biopharmaceutical company’s stock after selling 474 shares during the period. California State Teachers Retirement System owned about 0.08% of Agios Pharmaceuticals worth $1,586,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $33,000. GF Fund Management CO. LTD. purchased a new stake in Agios Pharmaceuticals during the 4th quarter worth about $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at about $53,000. Sterling Capital Management LLC lifted its holdings in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares in the last quarter.

Insider Buying and Selling

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company’s stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AGIO. Wall Street Zen lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 19th. Scotiabank decreased their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a report on Friday, May 2nd. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $56.50.

Agios Pharmaceuticals Trading Up 2.2%

AGIO stock opened at $34.33 on Monday. The company has a market cap of $1.99 billion, a PE ratio of 3.03 and a beta of 0.73. The stock has a 50-day moving average price of $28.98 and a two-hundred day moving average price of $34.23. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.86 million. Equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.